Smoking Cessation Intervention for Tobacco Users With Lung Nodules
(TeaMOUT Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the effectiveness of a smoking cessation outreach intervention (TeaM OUT) on increasing use of smoking cessation resources in Veterans. The hypotheses are 1) patients included in the TeaM OUT group will have higher accession of cessation services, such as counseling and medication therapies, compared to patients in enhanced usual care and 2) more patients in the TeaM OUT group will have quit smoking at one year after the intervention. Veterans with a recently diagnosed lung nodule who currently smoke will receive the TeaM OUT intervention or Enhanced Usual Care. The TeaM OUT intervention has 2 parts: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit Line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources. The enhanced usual care group will receive a letter that provides information about how to contact the IVR Quit Line. The IVR system will track referrals to cessation services. Additional information about smoking status and use of cessation resources will be collected from the electronic health record and surveys. .
Research Team
Christopher G. Slatore, MD MS
Principal Investigator
VA Portland Health Care System, Portland, OR
Eligibility Criteria
This trial is for Veterans who are active smokers and have recently been diagnosed with a lung nodule, under surveillance at specific VA Health Care Systems. There are no specific exclusion criteria, so all eligible veterans can participate.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Enhanced Usual Care (Behavioral Intervention)
- TeaM OUT Intervention (Behavioral Intervention)
Enhanced Usual Care is already approved in China for the following indications:
- Hepatic encephalopathy
- Constipation
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor
Dr. Grant Huang
VA Office of Research and Development
Acting Chief Research and Development Officer
PhD in Medical Psychology and Master of Public Health from the Uniformed Services University of Health Sciences
Dr. Erica M. Scavella
VA Office of Research and Development
Chief Medical Officer since 2022
MD from University of Massachusetts School of Medicine
Minneapolis Veterans Affairs Medical Center
Collaborator
Ralph H. Johnson VA Medical Center
Collaborator